Lentivirus‐mediated platelet gene therapy of murine hemophilia A with pre‐existing anti‐factor VIII immunity
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary. Background: The development of inhibitory antibodies, referred to as inhibitors, against exogenous factor VIII in a significant subset of patients with hemophilia A remains a persistent challenge to the efficacy of protein replacement therapy. Our previous studies using the transgenic approach provided proof‐of‐principle that platelet‐specific expression could be successful in treating hemophilia A in the presence of inhibitory antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Cited by
Evaluating and mitigating the immunogenicity of therapeutic proteins
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.008 · Cited by 118
Du, L. M., Nurden, P., Nurden, A. T., Nichols, T. C., Bellinger, D. A., Jensen, E. S., Haberichter, S. L., Merricks, E., Raymer, R. A., Fang, J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3773 · Cited by 119
Self-citationGao, C., Schroeder, J. A., Xue, F., Jing, W., Cai, Y., Scheck, A., Subramaniam, S., Rao, S., Weiler, H., Czechowicz, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000516 · Cited by 51
“Our previous studies have demonstrated that targeting factor VIII (FVIII) expression to platelets through hematopoietic stem cell (HSC)–based platelet-specific (2bF8) gene therapy restores hemostasis and induces immune tolerance in hemophilia A (HA) mice.(1-4) However, in our protocol, sufficient bone marrow (BM) prec…”
BackgroundSelf-citationState of the art: gene therapy of haemophilia
Spencer, H. T., Riley, B. E., & Doering, C. B. (2016) · Haemophilia · doi:10.1111/hae.13011 · Cited by 36
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“The rationale is that platelet-specific FIX or FVIII would be stored in the platelet a-granules, which may minimize the deleterious effect on clotting factor-dependent hemostasis from circulating factor inhibitors, as has been demonstrated in mice models by several groups [78-80].”
Background
Metadata
- Authors
- KUETHER, E. L., SCHROEDER, J. A., FAHS, S. A., COOLEY, B. C., CHEN, Y., MONTGOMERY, R. R., WILCOX, D. A., & SHI, Q.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 10
- Issue
- 8
- Pages
- 1570-1580
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W1510414151
- Cited by
- 103
- References
- 1
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lentivirus‐mediated platelet gene therapy of murine hemophilia A with pre‐existing anti‐factor VIII immunity. https://app.cochat.ai/papers/10.1111/j.1538-7836.2012.04791.x
- The paper
- KUETHER, E. L., SCHROEDER, J. A., FAHS, S. A., COOLEY, B. C., CHEN, Y., MONTGOMERY, R. R., WILCOX, D. A., & SHI, Q. (2012). Lentivirus‐mediated platelet gene therapy of murine hemophilia A with pre‐existing anti‐factor VIII immunity. Journal of Thrombosis and Haemostasis. https://doi.org/10.1111/j.1538-7836.2012.04791.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.